- Urethra-sparing stereotactic body radiotherapy (SBRT) shows favorable biochemical control rates and a low toxicity profile and maintains QoL regardless of overall treatment time (OTT) in patients with prostate cancer.
Why this matters
- SBRT shows good disease control, but information on the effect of OTT in terms of biochemical RFS is limited.
- Phase 2 study: 170 patients with prostate cancer were randomly assigned to urethra-sparing SBRT delivered either every other day (OTT, 10-12 days) or once a week (OTT, 30 days).
- Funding: Fundació Privada Cellex; Brianlab.
- All patients completed the treatment schedule.
- At week 12, patients reported:
- Satisfactory urinary QoL in both groups.
- Mild gastrointestinal toxicity, no grade 3 events, and
- No changes in gastrointestinal and genitourinary EORTC QLQ-PR25 scores.
- At week 18:
- 1 grade 3 genitourinary toxicity (obstructive symptoms) was reported (with a dose every other day).
- GI toxicity was mild with 70% of patients in both groups.
- Genitourinary EORTC QLQ-PR25 scores improved (median, 12 vs 8).
- Sexual domains (activity and functioning) remained stable.
- The EORTC QLQ-C30 global health status domain remained stable.
- 2 biochemical failures were reported in each group.
- Short follow-up.